全球人类狂犬病疫苗市场规模（按细胞株类型、应用、分销管道、区域覆盖范围和预测）

人类狂犬病疫苗市场规模及预测

2024 年人类狂犬病疫苗市场规模为 12.3 亿美元，预计到 2032 年将达到 19.1 亿美元，2026 年至 2032 年的复合年增长率为 5.7%。

• 人类用狂犬病疫苗是保护人类免受狂犬病毒感染的生技药品，通常由灭活的狂犬病毒体或病毒产生的重组蛋白组成。
• 这些疫苗刺激免疫系统形成针对狂犬病毒的抗体，以防止将来接触狂犬病毒。
• 人类狂犬病疫苗通常在接触病毒后注射在手臂上，或作为接触狂犬病动物高风险人群的预防措施，例如兽医、动物控制工作者和前往狂犬病常见地区的旅行者。
• 此外，人类狂犬病疫苗在预防狂犬病毒感染的致命后果方面发挥着重要作用。

狂犬病疫苗的全球市场动态

影响人类狂犬病疫苗市场的关键市场动态是：

关键市场驱动因素

• 全球狂犬病发生率上升：全球狂犬病发生率激增，主要原因是流浪犬攻击，这刺激了对人类狂犬病疫苗的需求。预防狂犬病感染需要全面的疫苗接种计划，这推动了市场扩张。
• 政府措施和疫苗接种计画：为了消除狂犬病，世界各国政府进行了宣传和疫苗宣传活动。这些计划通常包括免费或津贴疫苗接种，在促进人类狂犬病疫苗的使用和分发方面发挥重要作用。
• 疫苗研发的进展：细胞培养疫苗和重组疫苗等新型高效狂犬病疫苗的研发正在显着推动市场发展。这些疫苗的安全性和有效性均有所提升，并有望促进其更广泛地普及和使用。
• 旅行和前往狂犬病流行地区的次数增加：国际旅行，尤其是在狂犬病流行地区的旅行，会增加感染狂犬病的风险。这导致旅行者暴露前预防用药的增加，以及对人类狂犬病疫苗的需求增加。

主要挑战

• 高成本和高可及性：狂犬病疫苗价格昂贵，在偏远和欠发达地区又十分稀缺，这构成了重大障碍。这些限制因素限制了人们获得重要疫苗接种服务的机会，尤其是在狂犬病流行且最需要疫苗接种的地区。
• 低温运输物流与储存：狂犬病疫苗需要低温运输系统进行储存和运输，而该系统的维护难度较大，尤其是在资源匮乏的地区。低温运输中断会影响疫苗的有效性，为大规模疫苗宣传活动带来物流障碍，并限制市场扩张。
• 缺乏认知和教育：在许多狂犬病流行地区，人们对狂犬病和疫苗接种重要性的认知度较低。这种认识不足导致现有疫苗使用不足，阻碍了控制和消除狂犬病的努力。

主要趋势：

• 细胞培养疫苗的兴起：细胞培养疫苗作为传统鸡蛋疫苗的替代品，正日益受到欢迎。人们认为，细胞培养疫苗更安全、更有效、副作用更少，在暴露前和暴露后预防中越来越受欢迎。
• 免疫接种与数位健康记录整合：数位健康平台越来越多地被用于追踪免疫接种讯息，包括狂犬病疫苗接种情况。这种整合改善了对疫苗接种覆盖率和接种计划的监测，从而提高了免疫接种计画的效率和患者的依从性。
• 官民合作关係(PPP)：各国政府和医疗机构已与私人疫苗生产商达成协议，以提高狂犬病疫苗的可近性和可负担性。这些 PPP 旨在将疫苗接种计画扩大到服务匮乏的人群，并加强全球控制和消除狂犬病的努力。
• 重点在于单剂量疫苗研究：研发工作正转向开发有效的单剂量狂犬病疫苗。单剂量疫苗可以简化疫苗接种方法，提高遵从率，并缩短暴露后的反应时间。

目录

第一章 人用狂犬病疫苗全球市场介绍

• 市场定义
• 市场区隔
• 调查时间表
• 先决条件
• 限制

第 2 章 已验证的市场研究调查方法

• 资料探勘
• 数据三角测量
• 自下而上的方法
• 自上而下的方法
• 调查流程
• 业界专家的重要见解
• 资料来源

第三章执行摘要

• 市场概览
• 生态测绘
• 绝对的商机
• 市场吸引力
• 全球人类狂犬病疫苗市场区域分析
• 全球人类狂犬病疫苗市场（依细胞株类型）
• 全球人类狂犬病疫苗市场（按应用）
• 全球人类狂犬病疫苗市场（按分销管道）
• 未来市场机会
• 世界市场结构
• 产品生命线

4. 人类狂犬病疫苗的全球市场展望

• 世界各地人类狂犬病疫苗的演变
• 驱动程式
  • 司机1
  • 司机2
• 限制因素
  • 约束因素 1
  • 约束因素 2
• 机会
  • 机会1
  • 机会2
• 波特五力模型
• 价值链分析
• 定价分析
• 宏观经济分析

5. 全球人类狂犬病疫苗市场（依细胞株类型）

• 概述
• 鸡胚胎细胞
• Vero细胞
• BHK细胞
• 其他的

6. 全球人类狂犬病疫苗市场（依应用）

• 概述
• 暴露后预防
• 暴露前预防

7. 全球狂犬病疫苗市场（依分销管道）

• 概述
• 医院药房
• 零售药局
• 线上通路

8. 全球人类狂犬病疫苗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 拉丁美洲
  • 陶氏化学巴西
  • 阿根廷
  • 其他拉丁美洲
• 中东和非洲
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 其他中东和非洲地区

9. 全球人类狂犬病疫苗市场竞争格局

• 概述
• 各公司市场排名
• 主要进展
• 公司地理分布
• 公司在各行业的足迹
• ACE矩阵

第十章 公司简介

• Sanofi Pasteur
• Merck & Co.
• GSK
• Bavarian Nordic A/S
• China National Biotec Group Co.
• Wuhan Institute of Biological Products Co.
• The Serum Institute of India Ltd.
• Bharat Biotech International Limited
• Valneva SE
• Virbac SA

第十一章 重大进展

• 产品发布/开发
• 合併与收购
• 业务扩展
• 伙伴关係与合作

第十二章 已验证的市场情报

• 关于已验证的市场情报
• 动态资料视觉化

Human Rabies Vaccines Market Size And Forecast

Human Rabies Vaccines Market size was valued at USD 1.23 Billion in 2024 and is projected to reach USD 1.91 Billion by 2032, growing at a CAGR of 5.7% from 2026 to 2032.

• Human rabies vaccines are biologics that prevent humans from becoming infected with the rabies virus. They are usually composed of inactivated rabies virus particles or recombinant proteins produced from the virus.
• These vaccinations stimulate the immune system to develop antibodies against the rabies virus, protecting against future exposure.
• Human rabies vaccines are given in a series of injections, usually in the arm, after being exposed to the virus or as a preventive measure for people who are at high risk of encountering rabid animals, such as veterinarians, animal control workers, and travelers to areas where rabies is common.
• Moreover, human rabies vaccines play an important role in preventing the potentially lethal consequences of rabies virus infection.

Global Human Rabies Vaccines Market Dynamics

The key market dynamics that are shaping the Human Rabies Vaccines Market include:

Key Market Drivers:

• Growing Incidence of Rabies Worldwide: The global surge in rabies incidence, mainly in Asia and Africa as a result of stray dog attacks, has fueled demand for human rabies vaccines. Efforts to prevent rabies infections demand comprehensive vaccination programs, driving market expansion.
• Government Initiatives and Vaccination Programs: To eradicate rabies, governments around the world have started awareness and immunization campaigns. These programs frequently feature free or subsidized immunization, which is critical in promoting the use and distribution of human rabies vaccines.
• Advancements in Vaccine Development: The development of new and more efficient rabies vaccinations, such as cell culture and recombinant vaccines, has significantly boosted the market. These vaccines have improved safety and efficacy characteristics, encouraging greater adoption and use.
• Increased Travel and Exposure to Rabies-Prone Areas: There's a greater chance of contracting rabies when traveling internationally, particularly in regions where the disease is more common. This has resulted in an increase in pre-exposure prophylaxis among travelers, fueling the demand for human rabies vaccines.

Key Challenges:

• High Cost and Accessibility Issues: Rabies vaccines are expensive and scarce in remote or undeveloped areas, posing substantial obstacles. These constraints limit access to important vaccination services, particularly in locations where rabies is endemic and vaccinations are most needed.
• Cold Chain Logistics and Storage: Rabies vaccines necessitate a cold chain system for storage and transportation, which is challenging to maintain, particularly in low-resource areas. Breaks in the cold chain jeopardize vaccine efficacy, creating a logistical obstacle for extensive vaccination campaigns and limiting market expansion.
• Lack of Awareness and Education: Many rabies-endemic locations have a low level of awareness about the disease and the significance of vaccination. This lack of understanding resulted in the underuse of existing vaccines, impeding attempts to control and eradicate rabies.

Key Trends:

• Emergence of Cell Culture Vaccines: Cell culture vaccines are becoming increasingly popular as an alternative to traditional egg-based immunizations. Cell culture vaccines are seen as safer, more effective, and have fewer side effects, making them increasingly popular in both pre-exposure prophylactic and post-exposure therapies.
• Integration of Immunization with Digital Health Records: Digital health platforms are increasingly being utilized to track vaccination information, including rabies shots. This integration allows for improved monitoring of vaccine coverage and schedules, increasing the efficiency of immunization programs and patient compliance.
• Public-Private Partnerships (PPPs) for Vaccine Accessibility: Governments and healthcare groups are forging agreements with private-sector vaccine makers to improve rabies vaccine accessibility and affordability. These PPPs seek to expand immunization programs to underserved groups, thereby strengthening worldwide efforts to control and eliminate rabies.
• Focus on Research for Single-Dose Vaccines: Research and development efforts are increasingly centered on developing effective single-dose rabies vaccinations. A single-dose vaccine would simplify immunization methods, enhance compliance rates, and potentially accelerate response times in post-exposure settings, all of which would have a substantial impact on public health outcomes.

Global Human Rabies Vaccines Market Regional Analysis

Here is a more detailed regional analysis of the Human Rabies Vaccines Market:

Asia Pacific:

• According to Verified Market Research, Asia Pacific is estimated to dominate the Human Rabies Vaccines Market during the forecast period. Asia Pacific has some of the highest rates of rabies globally, partly due to massive stray dog populations in countries like India and China. This high frequency creates a significant need for human rabies vaccines, making the region an important market for these products.
• Governments in the Asia Pacific region have initiated aggressive rabies control and elimination programs, including mass vaccination of animals and humans. These measures considerably contribute to increased demand for rabies vaccines, which strengthens the market in this region.
• In the Asia Pacific region, public awareness of rabies and its prevention is increasing, due in part to educational efforts launched by health organizations and governments. This increased awareness has resulted in greater vaccination rates, which is fueling the market's growth.
• Furthermore, the Asia Pacific region's rapid development and extension of healthcare infrastructure, including increasing healthcare spending and the formation of new healthcare institutions, has expanded public access to vaccines. This infrastructure expansion enables more widespread distribution and administration of rabies vaccines.

Latin America:

• The expansion of urban areas in Latin America has resulted in more pet ownership and interaction with wildlife, increasing the danger of rabies spread. This tendency increases demand for pre-exposure prophylactic and post-exposure therapies, hence expanding the Human Rabies Vaccines Market.
• Many Latin American countries have carried out large rabies vaccination efforts for both animals and humans, particularly in rural and urban peripheral areas. These government-led programs are critical drivers of increased demand and distribution of rabies vaccines throughout the region.
• Furthermore, in Latin American countries, the growth of healthcare services and improved access to medical care have permitted increased vaccination coverage. This includes rural healthcare programs and the creation of clinics in underserved areas, which will drive the demand for rabies vaccines by making them more accessible to a larger population.

Middle East & Africa:

• The Middle East and Africa region has a high incidence of rabies cases, mostly due to stray dog populations and animals. This prevalence needs the continued and growing use of rabies vaccines, which drives market growth in both preventive and post-exposure therapies.
• Several nations in the region have initiated attempts to eradicate rabies, such as mass vaccination of animals and public health campaigns urging immunization. These initiatives by governmental and non-governmental organizations have considerably increased the demand for human rabies vaccines.
• Furthermore, International health organizations and philanthropists are increasingly sponsoring rabies prevention and control projects throughout the Middle East and Africa. This external financing and technical aid make vaccine procurement and distribution easier, increasing the region's ability to effectively combat rabies.

Global Human Rabies Vaccines Market: Segmentation Analysis

The Global Human Rabies Vaccines Market is segmented based on Cell Line Type, Application, Distribution Channel, And Geography.

Human Rabies Vaccines Market, By Cell Line Type

• Chick Embryo Cell
• Vero Cell
• BHK Cell
• Others

Based on Cell Line Type, the market is segmented into Chick Embryo Cells, Vero Cells, BHK Cells, and Others. The chick embryo cell segment is estimated to dominate the Human Rabies Vaccines Market due to the long-standing usage of chick embryo cells in the manufacture of rabies vaccines, which are known for their efficacy and safety. Vaccines made from chick embryo cell culture are widely used in immunization programs around the world, thanks in part to their long history of usage and thorough safety data. Furthermore, the synthesis procedure employing chick embryo cells is cost-effective and well-optimized, making these vaccines accessible and economical for large-scale immunization programs, particularly in underdeveloped countries where rabies is prevalent.

Human Rabies Vaccines Market, By Application

• Post-exposure Prophylaxis
• Pre-exposure Prophylaxis

Based on Application, the market is segmented into Post-exposure Prophylaxis and Pre-exposure Prophylaxis. The post-exposure prophylaxis segment is estimated to dominate the Human Rabies Vaccines Market during the forecast period due to the critical requirement for rabies vaccination following potential exposure to the rabies virus, which can be acquired by bites or scratches from infected animals. In many areas, particularly those where rabies is endemic, the danger of exposure is considerable, demanding early treatment to avoid the development of the disease, which is almost invariably fatal once symptoms appear. Post-exposure prophylaxis (PEP) entails delivering the rabies vaccination soon after exposure to prevent the virus from developing into an active disease.

Human Rabies Vaccines Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Channel

Based on the Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Channel. The hospital pharmacies segment is estimated to dominate the Human Rabies Vaccines Market during the forecast period due to the essential role hospital pharmacists play in administering post-exposure prophylaxis (PEP), which needs prompt medical attention. Hospitals are the major treatment locations for rabies exposures because they can give both the vaccination and the required immunoglobulins, as well as skilled medical monitoring. Furthermore, in many locations, rabies vaccines are provided as part of government-led health campaigns, with hospitals serving as the primary distribution and administration sites.

Key Players

• The "Human Rabies Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Sanofi Pasteur, Merck & Co., GSK, Bavarian Nordic A/S, China National Biotec Group Co., Wuhan Institute of Biological Products Co., The Serum Institute of India Ltd., Bharat Biotech International Limited, Valneva SE, Virbac SA, Crucell NV, Institute of Viral Diseases and CanSino Biologics Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Human Rabies Vaccines Market Recent Developments
• In December 2022, Everest Medicines announced the launch of a novel mRNA Rabies Vaccine development and the completion of a preclinical proof-of-concept study. This is a collaboration with Providence Therapeutics that focuses on a new rabies vaccine candidate.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HUMAN RABIES VACCINES MARKET

• 1.1 Market Definition
• 1.2 Market Segmentation
• 1.3 Research Timelines
• 1.4 Assumptions
• 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 2.1 Data Mining
• 2.2 Data Triangulation
• 2.3 Bottom-Up Approach
• 2.4 Top-Down Approach
• 2.5 Research Flow
• 2.6 Key Insights from Industry Experts
• 2.7 Data Sources

3 EXECUTIVE SUMMARY

• 3.1 Market Overview
• 3.2 Ecology Mapping
• 3.3 Absolute Market Opportunity
• 3.4 Market Attractiveness
• 3.5 Global Human Rabies Vaccines Market Geographical Analysis (CAGR %)
• 3.6 Global Human Rabies Vaccines Market, By Cell Line Type (USD Million)
• 3.7 Global Human Rabies Vaccines Market, By Application (USD Million)
• 3.8 Global Human Rabies Vaccines Market, By Distribution Channel (USD Million)
• 3.9 Future Market Opportunities
• 3.10 Global Market Split
• 3.11 Product Life Line

4 GLOBAL HUMAN RABIES VACCINES MARKET OUTLOOK

• 4.1 Global Human Rabies Vaccines Evolution
• 4.2 Drivers
  • 4.2.1 Driver1
  • 4.2.2 Driver 2
• 4.3 Restraints
  • 4.3.1 Restraint1
  • 4.3.2 Restraint 2
• 4.4 Opportunities
  • 4.4.1 Opportunity1
  • 4.4.2 Opportunity 2
• 4.5 Porters Five Force Model
• 4.6 Value Chain Analysis
• 4.7 Pricing Analysis
• 4.8 Macroeconomic Analysis

5 GLOBAL HUMAN RABIES VACCINES MARKET, BY CELL LINE TYPE

• 5.1 Overview
• 5.2 Chick Embryo Cell
• 5.3 Vero Cell
• 5.4 BHK Cell
• 5.5 Others

6 GLOBAL HUMAN RABIES VACCINES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Post-exposure Prophylaxis
• 6.3 Pre-exposure Prophylaxis

7 GLOBAL HUMAN RABIES VACCINES MARKET, BY DISTRIBUTION CHANNEL

• 7.1 Overview
• 7.2 Hospital Pharmacies
• 7.3 Retail Pharmacies
• 7.4 Online Channel

8 GLOBAL HUMAN RABIES VACCINES MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Dow Chemical Company Brazil
  • 8.5.2 Argentina
  • 8.5.3 Rest of Latin America
• 8.6 Middle-East and Africa
  • 8.6.1 UAE
  • 8.6.2 Saudi Arabia
  • 8.6.3 South Africa
  • 8.6.4 Rest of Middle-East and Africa

9 GLOBAL HUMAN RABIES VACCINES MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Developments
• 9.4 Company Regional Footprint
• 9.5 Company Industry Footprint
• 9.6 ACE Matrix

10 COMPANY PROFILES

• 10.1 Sanofi Pasteur
  • 10.1.1 Company Overview
  • 10.1.2 Company Insights
  • 10.1.3 Product Benchmarking
  • 10.1.4 Key Developments
• 10.2 Merck & Co.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 GSK
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Bavarian Nordic A/S
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 China National Biotec Group Co.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Wuhan Institute of Biological Products Co.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 The Serum Institute of India Ltd.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Bharat Biotech International Limited
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Valneva SE
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Virbac SA
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12. VERIFIED MARKET INTELLIGENCE

• 12.1 About Verified Market Intelligence
• 12.2 Dynamic Data Visualization